- Home
- PACB vs NMRA Comparison
PACB vs NMRA Comparison
Compare PACB & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACB | NMRA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.8M | 554.0M |
| IPO Year | 2010 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PACB | NMRA |
|---|---|---|
| Price | $1.65 | $1.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $1.67 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 6.4M | 4.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $93,468,000.00 | N/A |
| Revenue This Year | $11.32 | N/A |
| Revenue Next Year | $12.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.04 | N/A |
| 52 Week Low | $1.09 | $0.77 |
| 52 Week High | $2.73 | $3.65 |
Technical Indicators
Market Signals| Indicator | PACB | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 54.19 |
| Support Level | $1.52 | $1.76 |
| Resistance Level | $1.78 | $2.08 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 72.16 | 97.03 |
Price Performance
Historical ComparisonAbout PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.